2011年12月，美国食品与药物管理局（FDA）批准了对Nplate（罗米司亭）和Promacta（艾曲泊帕）风险评估与减缓策略（REMS）的修改。这些修改包括取消了对参加REMS项目的某些规定。
基于208个网页-相关网页
In those patients who did not receive Nplate, only one experienced a sustained increase in platelet counts.
在这些没有接收Nplate治疗患者中，只有一个出现了持续增长的血小板计数。
Nplate is approved only for patients with chronic ITP who do not respond sufficiently to current treatments.
Nplate只是被批准用于那些对于目前的治疗方法无反应得慢性ITP患者。
The response to Nplate was higher in those patients who still had their spleen than in those patients who had undergone a splenectomy.
有脾脏的病人比那些接受脾切除术病人对于Nplate的反应更高。
应用推荐